MaxCyte stock edges higher as analysts stick to Strong Buy rating

Published on 09/18/2026 at 18:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MaxCyte stock closed at USD 1.20 on September 17, 2026 on Nasdaq, with analysts maintaining a Strong Buy consensus and an average price target of USD 4.11. The latest reported quarterly revenue stood at USD 7.3 million with a net loss of USD 9.6 million in Q4 2025.

MXCT, US57777K1060, Illustration mit AI erstellt.

MaxCyte, Inc. stock (ISIN US57777K1060) closed at USD 1.20 on Nasdaq on September 17, 2026, up 1.27% from the prior close, giving the cell-engineering specialist a market capitalization of about USD 123.3 million based on data from Yahoo Finance as of that date.

Analysts keep Strong Buy stance with upside targets

According to Yahoo Finance on September 17, 2026, analysts covering MaxCyte maintain a Strong Buy recommendation on the stock, with an average 12-month price target of USD 4.11 versus the current price of USD 1.20. This implies upside of about 242% if the consensus target were reached, underlining how far the shares still trade below what analysts see as fair value.

The same overview shows a high price target of USD 5.00 on MaxCyte as of September 17, 2026, compared with the USD 1.20 closing level that day, highlighting a gap of USD 3.80 between the most optimistic target and the latest price. For investors, this wide spread between current trading levels and analyst expectations is a key part of the risk-reward profile.

Recent fundamentals show ongoing losses despite revenue base

In its most recently reported quarter, MaxCyte generated revenue of USD 7.3 million and posted a net loss of USD 9.6 million in Q4 2025, according to the quarterly figures summary presented on Yahoo Finance. These figures, which represent the latest available quarterly data up to September 18, 2026, confirm that the company is still loss-making despite its established revenue base.

Based on the trailing twelve-month data in the same source, MaxCyte's earnings per share stand at negative USD 0.34 as of September 17, 2026, reflecting the cumulative impact of operating losses over the past year. This negative EPS contrasts with the stock's year-to-date price performance of 22.90% and 1-year return of 20.33%, as reported by Yahoo Finance, indicating that the share price has recovered even while profitability remains elusive.

Stock performance, volatility and upcoming earnings date

Per Yahoo Finance on September 17, 2026, MaxCyte stock closed at USD 1.1950 on Nasdaq, up 1.27% from the previous close, with an intraday trading volume of 257,586 shares versus an average volume of about 1,049,491 shares. The stock's beta over the past five years is listed at 1.53, suggesting above-average volatility compared with the broader market, which can amplify both gains and losses for shareholders.

The same data indicate that MaxCyte's year-to-date return of 22.90% compares favorably with the S&P 500 index's 11.57% over the same period, while its 1-year return of 20.33% also exceeds the S&P 500's 15.72% performance. This means MaxCyte has outperformed the large-cap benchmark by 11.33 percentage points year-to-date and by 4.61 percentage points over the past year, even though its market cap remains modest at roughly USD 123.3 million as of September 17, 2026.

Closing price context for MaxCyte stock

As of the Nasdaq session on September 17, 2026, MaxCyte stock closed at USD 1.1950, with the after-hours indication at the same level, according to data cited by Yahoo Finance. For investors, this relatively low absolute price level, combined with the Strong Buy analyst consensus and negative trailing earnings, frames MaxCyte as a high-volatility, high-upside but still loss-making life sciences play.